FAST NEWS: InnoCare’s loss narrows on higher lymphoma drug sales
The latest: InnoCare Pharma Ltd. (9969.HK) announced on Monday its third quarter revenue dropped 18.3% year-over-year to 160 million yuan ($21.9 million), while its net loss narrowed 72.2% to 109 million yuan.…
FAST NEWS: InnoCare inches closer to profitability on strong sales gains
The latest: InnoCare Pharma Ltd. (9969.HK) announced Tuesday its first-quarter revenue jumped 59% year-over-year to 189 million yuan ($27.3 million), while its net loss narrowed 90% to 12.41 million yuan. Looking…
FAST NEWS: InnoCare Pharma’s Loss Soars on R&D Costs, Exchange Losses
The latest: InnoCare Pharma Ltd. (9969.HK) said it expects to report its net loss soared about 13 times to 910 million yuan ($134 million) last year, according to a profit…
InnoCare Revs Up for Next Phase With Strong Results, IPO Plan
Sales of the company’s key Orelabrutinib cancer drug doubled in the first half of the year, contributing to a 142% revenue jump for the period Key Takeaways: InnoCare Pharma’s revenue…
FAST NEWS: InnoCare Pharma Losses Double on Higher Costs And Exchange Deficit
The latest: InnoCare Pharma Ltd. (9969.HK) issued a profit warning Friday, estimating a net loss of no more than 495 million yuan ($73 million) for the first half of this year,…
FAST NEWS: InnoCare Pharma Granted Production Approval for Guangzhou Facility
The latest: InnoCare Pharma Ltd. (9969.HK) announced Monday its Guangzhou manufacturing facility has been approved by the China National Medical Products Administration (NMPA) to start the production of commercial supply of its…
FAST NEWS: InnoCare Pharma Sees Losses Shrinking, But Stock Still Slumps
The latest: Drug maker InnoCare Pharma Ltd. (9969.HK) announced Wednesday evening that it expects to report a net loss of up to 100 million yuan ($15.7 million) for all 2021,…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
Everest reaches new heights on growing drug sales
1952.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
